Biosino Bio-Technology and Science Incorporation provided unaudited consolidated earnings guidance for the year ended 31 December 2023. for the year, Group is expected to record a net loss within a range of RMB 18,000,000 to RMB 22,000,000 for the Reporting Period as compared to a net profit of approximately RMB 14,202,000 for the year ended 31 December 2022. The Board considers that the expected loss for the Reporting Period is mainly attributable to (i) a decrease in the Group's gross profit due to (a) a drop in market demand as affected by changes in public health prevention and control policies both domestically and abroad; and (b) a drop in price of products as affected by industry centralised procurement; and (ii) an increase in the Group's research and development expenses on the its advantageous products, such as flow cytometry and supporting reagents.
Biosino Bio-Technology and Science Incorporation
Equities
8247
CNE100000288
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.59 HKD | -6.35% |
|
-6.35% | -26.25% |
1st Jan change | Capi. | |
---|---|---|
-26.25% | 11.68M | |
-7.01% | 12.28B | |
+98.23% | 8.54B | |
-22.31% | 6.58B | |
+7.73% | 5.77B | |
-23.82% | 3.48B | |
+5.84% | 2.54B | |
+40.39% | 2.41B | |
-7.55% | 2.3B | |
-68.46% | 2.07B |
- Stock Market
- Equities
- 8247 Stock
- News Biosino Bio-Technology and Science Incorporation
- Biosino Bio-Technology and Science Incorporation Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023